Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. Questo articolo non è disponibile.
Lingua: inglese
Editore: Biohealthcare Pub, 2012
- Rilegato
- Nuovo

Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books
Venditore con 5 stelle
Venditore AbeBooks dal 6 gennaio 2003
Non disponibile
Rilegato
Condizione: Nuovo
EUR 252,15
Descrizione dell’articolo da parte del venditore
1st edition. 400 pages. 9.25x6.25x1.75 inches. In Stock.
Codice articolo __1907568379
- Titolo
- Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry
- Autore
- Strohl, William R/ Strohl, Lila M
- Editore
- Biohealthcare Pub
- Anno di pubblicazione
- 2012
- Condizione
- Brand New
- Rilegatura
- Hardcover
- Lingua
- inglese
- ISBN 10
- 1907568379
- ISBN 13
- 9781907568374
- Peso dell'articolo
- 1,15 chilogrammi
The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering.
"Riassunto" può appartenere a un’altra edizione di questo titolo.
Informazioni sull’autore
Dr. William R. Strohl is Vice President of Biologics Research at J&J Biotechnology Center of Excellence, Pennsylvania. From 2001 to 2008, Dr. Strohl was a leader in Merck's efforts to develop therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies.
Lila M. Strohl is a Member of the Association of Medical Illustrators and is a Certified Medical Illustrator. She has worked as the Head of Medical Illustration at St Anthony Medical Center, Columbus, Ohio, as a staff Medical Illustrator in the department of Biomedical Communications at The Ohio State University, USA , and is currently owner of Biomedscapes, a medical and scientific art company.
Lila M. Strohl is a Member of the Association of Medical Illustrators and is a Certified Medical Illustrator. She has worked as the Head of Medical Illustration at St Anthony Medical Center, Columbus, Ohio, as a staff Medical Illustrator in the department of Biomedical Communications at The Ohio State University, USA , and is currently owner of Biomedscapes, a medical and scientific art company.
"Descrizione articolo" può appartenere a un’altra edizione di questo titolo.